Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2070]

A variety of approaches to measure the efficacy of PARP inhibitors

Dr Elisabetta Leo - AstraZeneca, Cambridge, UK

A variety of approaches to measure the efficacy of PARP inhibitors ( Dr Elisabetta Leo - AstraZeneca, Cambridge, UK )

Development and clinical indications of PARP inhibitors

Dr Mark O'Connor - AstraZeneca, Cambridge, UK

Development and clinical indications of PARP inhibitors ( Dr Mark O'Connor - AstraZeneca, Cambridge, UK )

Mechanisms and prospects of a novel CDK9 inhibitor for DLBCL

Dr Susan Galbraith - AstraZeneca, Cambridge, UK

Mechanisms and prospects of a novel CDK9 inhibitor for DLBCL ( Dr Susan Galbraith - AstraZeneca, Cambridge, UK )

Front-line therapy of DIPG using IDO inhibitor with radiation and chemotherapy

Dr Theodore Johnson - Georgia Cancer Center, Augusta, USA

Front-line therapy of DIPG using IDO inhibitor with radiation and chemotherapy ( Dr Theodore Johnson - Georgia Cancer Center, Augusta, USA )

Impact of microbiome on head and neck cancers

Dr Young Jun Kim - Vanderbilt-Ingram Cancer Center, Nashville, USA

Impact of microbiome on head and neck cancers ( Dr Young Jun Kim - Vanderbilt-Ingram Cancer Center, Nashville, USA )

First-in-human trial results of RET targeted BLU-667

Prof Vivek Subbiah - MD Anderson Cancer Center, Houston, USA

First-in-human trial results of RET targeted BLU-667 ( Prof Vivek Subbiah - MD Anderson Cancer Center, Houston, USA )

Treating RET alterations with novel therapy BLU-667

Prof Vivek Subbiah - MD Anderson Cancer Center, Houston, USA

Treating RET alterations with novel therapy BLU-667 ( Prof Vivek Subbiah - MD Anderson Cancer Center, Houston, USA )

Tandem duplications in triple negative breast cancer

Dr Ed Liu - The Jackson Laboratory, Bar Harbor, USA

Tandem duplications in triple negative breast cancer ( Dr Ed Liu - The Jackson Laboratory, Bar Harbor, USA )

Effects of dasatinib on xenograft lung tumour models with YES1 overexpression

Dr Irati Garmendia - University of Navarra, Pamplona, Spain

Effects of dasatinib on xenograft lung tumour models with YES1 overexpression ( Dr Irati Garmendia - University of Navarra, Pamplona, Spain )

Results from GOBACK: Non-chromosomal birth defects linked with cancer

Dr Jeremy Schraw - Baylor College of Medicine, Houston, USA

Results from GOBACK: Non-chromosomal birth defects linked with cancer ( Dr Jeremy Schraw - Baylor College of Medicine, Houston, USA )

Novel gene biomarkers in multiple cancers derived from non-malignant breast...

Jon Obenauer - Rancho BioSciences, Rancho Santa Fe, USA

Novel gene biomarkers in multiple cancers derived from non-malignant breast phenotypes ( Jon Obenauer - Rancho BioSciences, Rancho Santa Fe, USA )

Response and safety profile of neoadjuvant nivolumab for resectable lung cancer

Dr Drew Pardoll - Johns Hopkins Medicine, Baltimore, USA

More from ecancer